Published in AIDS Weekly, December 16th, 2002
Fuzeon is the frontrunner in a new class of anti-HIV drugs called "fusion inhibitors," developed for the treatment of HIV-1 infection in combination with other antiretroviral agents.
Roche and Trimeris have requested priority review status from the FDA, which if granted would enable Fuzeon to be reviewed within 6 months.
In parallel with the filing, Roche and Trimeris confirmed the successful completion of the next major...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.